BioPharm International-06-01-2003

by BioPharm International staff

by Peter Loupos, Aventis Drug Innovation and Approval and Andrew Grygiel A collaborative framework can be a driver for cultural change, encouraging knowledge sharing between internal and external personnel and improving innovation and productivity throughout the enterprise.

by Chandrashekar Ganesa, Genzyme Corporation, Brian W. Granda, and Robert J. Mattaliano

In Search of the Optimum biotech Strategy

June 15, 2003

by Penny Cass, BioPharm International Stay current on the changes in corporate governance regulations ? whether your company is public or private, in the United States or elsewhere. As a capital-intensive industry, many of our third-party associations are going to require that biopharmaceutical companies comply with the new regulations to receive financing. The trend to regulate corporate governance activities hasn't ended ? more rules promulgated by more government entities should be anticipated.

by Ellis Wilson, AstraZeneca Pharmaceuticals, James McDonough, William Allbee, and Jann Nielsen Compared with their big pharma counterparts, biotech project managers earn more advanced degrees, have fewer years' experience in the industry, and more frequently classify their role as "senior management."

by Bruce Babbitt, PAREXEL International, JanHasker Jonkman, and Paul McKim By partnering with external drug development service providers, small biopharmaceutical start-ups can move their products out of the lab and into clinical development more efficiently.

Columns and Departments

June 15, 2003

by Jill Wechsler, BioPharm International FDA is examining policy options for incorporating genomic information into the regulatory process while encouraging manufacturers to share pharmacogenomic research.

Columns and Departments

June 15, 2003

by Desiree de Myer, BioPharm International Despite market conditions favorable to merger and acquisition activity, a frenzy of consolidations still hasn't taken place.